Substituted heterocyclyl derivatives as CDK inhibitors

1. A compound of formula (IB):

or a pharmaceutically acceptable salt or a stereoisomer thereof;

wherein,

ring B is phenyl, piperidinyl, pyridinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, pyrazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl;

R 2 is (C 1 - C 6 )alkyl or (C 3 - C 10 )cycloalkyl;

R 3 is hydrogen or (C 1 - C 6 )alkyl;

R 4 at each occurrence is halo;

R 5 is

wherein R 5 ′ is hydrogen, halo, methoxymethyl or —CH 2 —NR a R b ; R 5 ″ is H;

R a and R b are each independently (C 1 - C 6 )alkyl, (C 1 - C 6 )alkoxy or methoxyethyl; alternatively, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted 5 to 6 membered ring containing 0-2 additional heteroatoms that are independently N, O or S; wherein the optional substituent is one or more halo, cyano, cyano(C 1 -C 6 )alkyl, methoxymethyl or —COO-(C 1 -C 6 )alkyl or a combination thereof;

R 6 at each occurrence is halo, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy;

L 1 is *—CR c R d —C(O)— or absent; wherein * is point of attachment with phenyl ring;

R c and R d independently are hydrogen or (C 1 -C 6 )alkyl; alternatively, R c and R d together with the carbon atom to which they are attached form a (C 3 -C 10 )cycloalkyl ring;

L2 is —C(O)NH— or absent;

m is 0 or 1; and

q is 0 to 2.

2. The compound of claim 1 , having formula (ID):

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

3. The compound of claim 1 , having formula (IE):

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;

wherein, L 1 is *—CR c R d —C(O)—; wherein * is point of attachment with the phenyl ring.

4. The compound of claim 1 , having a compound of formula (IF):

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;

wherein,

R 3 is hydrogen;

R5 is

wherein R 5 ′ is hydrogen, methoxymethyl or —(CH 2 )—NR a R b ; R 5 ″ is H;

R a and R b are each independently (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or methoxyethyl;

alternatively, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted 5 to 6 membered heterocyclic ring containing 0-2 additional heteroatoms that are independently N, O or S; wherein the optional substituent is one or more halo, cyano, cyano(C 1 -C 6 )alkyl, methoxymethyl or —COO-(C 1 -C 6 )alkyl or a combination thereof;

L 1 is *—CR c R d —C(O)—; wherein * is point of attachment with phenyl ring;

R c and R d independently are hydrogen or (C 1 -C 6 )alkyl; alternatively, R c and R d together with the carbon atom to which they are attached form a (C 3 -C 10 )cycloalkyl ring; and

m is 0 and R4 is absent.

5. The compound according to claim 1 , wherein ring B is phenyl or pyridinyl.

6. The compound according to claim 1 , wherein R 2 is cyclopropyl.

7. The compound according to claim 1 , wherein R 5 is

8. The compound according to claim 7 , wherein R 5 ′ is (CH 2 ) 2 —NR a R b ; wherein R a and R b are each independently (C 1 -C 6 )alkyl; alternatively, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted 5 to 6 membered heterocyclic ring containing 0-2 additional heteroatoms that are independently O, S or N; wherein the optional substituent independently is one or more halo.

9. The compound according to claim 8 , wherein R a and R b together with the nitrogen atom to which they are attached form a 5 to 6 membered heterocyclic ring containing 0-2 additional heteroatoms that are independently O, S or N.

10. The compound according to claim 1 , wherein L 1 is *—CR c R d —C(O)—; wherein * is the point of attachment with the phenyl ring.

11. The compound according to claim 1 , wherein L 2 is absent.

12. The compound of claim 1 selected from the group consisting of:

Compound

No.

IUPAC name

1

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide;

2

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide (Isomer-1 of compound-1);

3

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide (Isomer-2 of compound-1);

4

(E)-N-(5′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-2′-fluoro-

[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide;

5

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-4′-fluoro-

[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide;

7

(E)-N-(3′-(2-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-2-oxoethyl)-[1,1′-biphenyl]-4-

yl)-4-(dimethylamino)but-2-enamide;

8

(E)-4-(dimethylamino)-N-(3′-(1-((5-ethyl-

1H-pyrazol-3-yl)amino)-1-oxopropan-2-

yl)-[1,1′-biphenyl]-4-yl)but-2-enamide;

9

(E)-N-(3′-(1-((5-(tert-butyl)-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide;

13

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxobutan-2-yl)-[1,1′-

biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide;

14

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide;

15

(E)-N-(3′-(1-((5-cyclobutyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide;

16

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-3-yl)-4-(dimethylamino)but-

2-enamide;

17

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-2-fluoro-

[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide;

18

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)acrylamide;

19

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1′-

biphenyl]-4-yl)acrylamide;

20

N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)acrylamide;

21

N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)acrylamide

(Isomer-1 of compound-20);

22

N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)acrylamide

(Isomer-2 of compound-20);

23

N-(5′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-2′,3-difluoro-

[1,1′-biphenyl]-4-yl)acrylamide;

24

N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-3-yl)acrylamide;

25

2-(4′-acrylamido-3′-fluoro-[1,1′-biphenyl]-

3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-

3-methylbutanamide;

26

2-(3-(5-acrylamidopyridin-2-yl)phenyl)-

N-(5-cyclopropyl-1H-pyrazol-3-

yl)butanamide;

27

2-(4′-acrylamido-3′-fluoro-[1,1′-biphenyl]-

3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-

yl)butanamide;

28

(E)-N-(3′-(1-((5-cyclopentyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide;

29

(E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-

(3-(1-(4-(dimethylamino)but-2-

enoyl)indolin-5-yl)phenyl)propanamide;

30

N-(3′-(1-((5-cyclopropyl-4-methyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-4-yl)acrylamide;

31

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxobutan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-

2-enamide;

32

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-(diethylamino)but-2-enamide;

33

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-(pyrrolidin-1-yl)but-

2-enamide;

34

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-morpholinobut-2-enamide;

35

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-3-yl)-4-morpholinobut-2-enamide;

36

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-

yl)phenyl)pyridin-3-yl)-4-(dimethylamino)but-

2-enamide;

37

(E)-4-((6-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-3-yl)amino)-N,N-

dimethylbut-2-enamide;

38

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-

2-fluoropyridin-3-yl)-4-(dimethylamino)but-

2-enamide;

39

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-3-yl)-4-(piperidin-1-yl)but-

2-enamide;

40

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(piperidin-1-yl)but-

2-enamide;

41

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-methoxybut-2-enamide;

42

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-

2-enamide;

43

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-3-methyl-1-oxobutan-2-yl)-3-

fluoro-[1,1′-biphenyl]-4-yl)-4-

(dimethylamino)but-2-enamide;

45

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(3-fluoropyrrolidin-

1-yl)but-2-enamide;

46

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((S)-3-

fluoropyrrolidin-1-yl)but-2-enamide;

47

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-

1-yl)but-2-enamide (Isomer-1 of

compound-46);

48

E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-

1-yl)but-2-enamide (Isomer-2 of

compound-46);

49

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((R)-3-

fluoropyrrolidin-1-yl)but-2-enamide

50

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-

1-yl)but-2-enamide (Isomer-1 of

compound-49);

51

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-

1-yl)but-2-enamide (Isomer-2 of

compound-49);

55

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(diethylamino)but-

2-enamide;

56

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-3-methyl-1-oxobutan-2-

yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-

2-enamide;

57

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(3-fluoropiperidin-

1-yl)but-2-enamide;

58

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)phenyl)-

2-fluoropyridin-3-yl)-4-morpholinobut-2-enamide;

59

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)phenyl)-

6-fluoropyridin-2-yl)-4-morpholinobut-2-enamide;

60

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-3-yl)-4-morpholinobut-2-enamide;

61

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-yl)-[1,1′-

biphenyl]-3-yl)-4-morpholinobut-2-enamide;

62

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-

(methoxy(methyl)amino)but-2-enamide;

63

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)phenyl)-

3-fluoropyridin-2-yl)-4-morpholinobut-2-enamide;

64

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)phenyl)-

2-fluoropyridin-3-yl)-4-(3-fluoropyrrolidin-

1-yl)but-2-enamide;

65

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-

1-oxopropan-2-yl)-3-methoxy-

[1,1′-biphenyl]-4-yl)acrylamide;

66

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-

1-oxopropan-2-yl)-3-methyl-[1,1′-

biphenyl]-4-yl)acrylamide;

67

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-

1-oxopropan-2-yl)-3,5-dimethyl-

[1,1′-biphenyl]-4-yl)acrylamide;

68

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((2-

methoxyethyl)(methyl)amino)but-2-enamide;

69

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(1H-imidazol-

1-yl)but-2-enamide;

70

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((S)-2-

(methoxymethyl)pyrrolidin-1-yl)but-2-enamide;

71

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((S)-2-

(methoxymethyl)pyrrolidin-1-yl)but-2-enamide

(Isomer-1 of compound-70);

72

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((S)-2-

(methoxymethyl)pyrrolidin-1-yl)but-2-enamide

(Isomer-2 of compound-70);

73

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-2-methoxy-

[1,1′-biphenyl]-4-yl)acrylamide;

74

N-((5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)methyl)acrylamide;

75

N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-2-methyl-[1,1′-

biphenyl]-4-yl)acrylamide;

76

2-(3-(1-acryloylindolin-5-yl)phenyl)-

N-(5-cyclopropyl-1H-pyrazol-3-

yl)propanamide;

77

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-((2S,4S)-4-

fluoro-2-(methoxymethyl)pyrrolidin-1-yl)but-

2-enamide;

78

(E)-4-(3-cyanopyrrolidin-1-yl)-N-(5-(3-(1-

((5-cyclopropyl-1H-pyrazol-3-yl)amino)-

1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-

2-enamide;

79

N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyrazin-2-yl)acrylamide;

80

(E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-

yl)amino)-1-oxopropan-2-yl)-3-fluoro-

[1,1′-biphenyl]-4-yl)-4-((S)-3-

fluoropyrrolidin-1-yl)but-2-enamide;

81

methyl ((E)-4-((5-(3-(1-((5-cyclopropyl-1H-

pyrazol-3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)amino)-4-oxobut-

2-en-1-yl)-L-prolinate;

82

(E)-4-((S)-2-(cyanomethyl)pyrrolidin-1-yl)-

N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)but-2-enamide;

83

4-acrylamido-N-(3-((5-ethyl-1H-pyrazol-

3-yl)amino)phenyl)benzamide;

84

(E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-

(3-(1-(4-(dimethylamino)but-2-enoyl)-

1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide;

85

(E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-

2-(3-(1-(4-(dimethylamino)but-2-

enoyl)piperidin-4-yl)phenyl)propanamide;

86

N-(3′-(2-((5-methyl-1H-pyrazol-3-yl)amino)-

2-oxoethyl)-[1,1′-biphenyl]-4-

yl)acrylamide;

87

N-(3′-(1-((5-ethyl-1H-pyrazol-3-yl)amino)-

1-oxopropan-2-yl)-[1,1′-biphenyl]-4-

yl)acrylamide;

88

N-(3′-(1-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-

1-oxopropan-2-yl)-[1,1′-biphenyl]-

4-yl)acrylamide;

89

(E)-N-(3-((1H-indazol-3-yl)amino)phenyl)-

4-(4-(dimethylamino)but-2-

enamido)benzamide;

90

N-(3′-(1-((1H-indazol-3-yl)amino)-

1-oxopropan-2-yl)-[1,1′-biphenyl]-4-

yl)acrylamide;

91

(E)-N-(3′-(1-((1H-indazol-3-yl)amino)-1-

oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)-4-

(dimethylamino)but-2-enamide;

92

(E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyrazin-2-yl)-4-(pyrrolidin-1-

yl)but-2-enamide;

93

(S,E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-morpholinobut-

2-enamide;

94

(E)-N-(5-cyclopropyl-1H-pyrazol-3-

yl)-1-(3-(6-(4-(pyrrolidin-1-yl)but-2-

enamido)pyridin-3-yl)phenyl)cyclopropane-

1-carboxamide; and

95

(E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-

3-yl)amino)-2-methyl-1-oxopropan-2-

yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-

2-enamide;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

13. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof and at least one pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition comprising the compound of claim 12 , or pharmaceutically acceptable salt or a stereoisomer thereof, and at least one pharmaceutically acceptable carrier or excipient.